Achema with bioeconomy highlights
Enlarge image


Achema with bioeconomy highlights

22.06.2012 - Finale at ACHEMA: The world's biggest fair for chemical engineering, biotechnology and environmental protection delivers its final day.

Frankfurt – The fair brings together more than 180,000 participants and 3,770 exhibitors from 56 countries. Hot topics at ACHEMA 2012 are energy and resources. With BiobasedWorld, the organisers have introduced a special industrial biotechnology and biomass processing focus, mirroring how the knowledge-based bioeconomy has started to transform the chemical industry. The bioeconomy is not only a special focus amongst exhibitors, but was also covered by its own "BiobasedWorld" conference.

The importance of the subject was highlighted by a group of 30 science and industry experts from Germany presenting  the "Roadmap Biorefineries". This paper, worked out on behalf of the Federal Government , includes a SWOT analysis on the potential of available biorefinery technologies as well as fields where further research and development efforts are necessary by the year 2030.

Georg Schütte, State Secretary in the Federal Ministry for Education and Research, also introduced three strategic alliances in industrial biotechnology. In these alliances, partners from industry and research from a variety of industry branches work together to foster “biologisation” of industry and to deliver novel biobased products. The alliance "ZeroCarbon Footprint" , coordinated by energy giant RWE Power AG , will have a total volume of €46m, from which the half is financed by public money. It focuses on using carbon-rich waste streams as a basis for novel biotech products. The alliance "Functionalisation of polymers", coordinated by enzyme specialist Evocatal, will see the government und the respective industry partners investing €8m in total. The cosmetics and nutraceuticals alliance "NatLifE", coordinated by BRAIN AG, will have a total volume of €30m.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • WILEX (D)2.20 EUR10.00%
  • DEINOVE (F)6.85 EUR7.54%


  • IMMUPHARMA (UK)28.50 GBP-12.98%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.08 EUR43.7%
  • OREXO (S)65.25 SEK40.9%
  • ZEALAND PHARMA (DK)155.00 DKK26.0%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • IMMUPHARMA (UK)28.50 GBP-30.1%


  • KARO BIO (S)43.10 SEK5221.0%
  • CHRONTECH PHARMA (S)0.34 SEK325.0%
  • GALAPAGOS (B)38.85 EUR237.5%


  • NEOVACS (F)0.72 EUR-76.7%
  • BIOTEST (D)19.00 EUR-74.8%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 09.10.2015